A Phase 3 interventional study of Dual trigger and hCG (standard) in Poor Ovarian Reserve, sponsored by American University of Beirut Medical Center. Completed at 1 site in Lebanon. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-23.
Sponsored by American University of Beirut Medical Center · Phase 3, Interventional, and Treatment
This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in patients with poor ovarian reserve seeking IVF/ICSI treatment.
Women with POR (Bologna criteria) manifest a very low follicular response to controlled ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of oocyte maturation was shown to improve follicle collection yield and oocyte maturation in women with predicted normal ovarian response. These benefits have been attributed to the GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion. The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for final oocyte maturation improve oocyte collection and maturation rate
American University of Beirut Medical Center is the lead sponsor of 152 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dual trigger: (0.3 mg GnRHa = triptorelin) with + HCG (Choriomon)10 000 IU . will be administered subcutaneously in a single dose 0.3 mg with 10 000 HCG when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
Drug: Dual trigger
HCG (Choriomon) of 10 000 IU will be administered subcutaneously in a single dose when at least 2 follicles 18 mm in diameter have been observed by ultrasound examination.
Drug: hCG (standard)
Dual trigger: human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once) + Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)
Also known as: Dual ovulation trigger (Choriomon and Triptorelin)
human Chorionic Gonadotropin (Choriomon 10,000 IU subcutaneous once)
Also known as: human Chorionic Gonadotropin
Number of oocytes retrieved (oocyte collection rate)
the total number of oocytes retrieved divided by the number of follicles aspirated (diameter ≥10 mm) on the day of oocyte retrieval
Time frame: 38 hrs
Number of mature oocytes (oocyte maturation rate)
the ratio of MII oocytes to the number of collected oocytes
Time frame: 38 hrs
Fertilization rate
the ratio of normal fertilized oocytes (2PN) to the number of oocytes used for fertilization
Time frame: 48 hrs
Clinical pregnancy rate
the presence of fetal cardiac activity confirmed by transvaginal ultrasound 7 weeks after embryo transfer
Time frame: 7 weeks
Implantation rate
the number of gestational sacs visualized on ultrasound examination divided by the number of embryos transferred
Time frame: 7 weeks
Miscarriage rate
the spontaneous loss of a clinical pregnancy occurring before 12 completed weeks of gestational age
Time frame: 12 weeks
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
American University of Beirut Medical Center